Prita Riana Asih

Prita Riana Asih
Macquarie University · Department of Biomedical Sciences

29.06
 · 
Doctor of Philosophy

About

28
Publications
2,480
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
192
Citations
Introduction
I am passionate about neuroscience or biomedical research focussing on Alzheimer's disease and its application for the benefit of people. I have PhD in molecular biology/neuroscience and have extensive experience in both basic science and clinical trials. In addition, I have teaching experience (private mentoring and in class). Currently working as Research Associate at Dementia Research Centre, Macquarie University.
Research Experience
June 2019 - October 2019
Macquarie University
Position
  • Research Associate
March 2015 - March 2019
UNSW Sydney
Position
  • PhD Student
Description
  • Investigate the role of Translocator protein in neurodegenerative diseases.
June 2014 - February 2015
National Institute of Radiological Sciences
Position
  • Trainee
Description
  • Translocator protein (TSPO) ligands as a potential treatment of Alzheimer's disease.

Publications

Publications (28)
Article
Full-text available
Background/objective: Hepcidin, an iron-regulating hormone, suppresses the release of iron by binding to the iron exporter protein, ferroportin, resulting in intracellular iron accumulation. Given that iron dyshomeostasis has been observed in Alzheimer's disease (AD) together with elevated serum hepcidin levels, the current study examined whether...
Article
Full-text available
Background: Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer's disease amyloid pathology (amyloid-β; Aβ), and neuroinflammation (kynurenine pathway; KP metabolites) have been investigated independently in neurodegenerative diseases. However, the association of these markers of neurodegeneration and AD patho...
Article
Background: Aberrant amyloid-β (Aβ) deposition in the brain occurs two decades prior to the manifestation of Alzheimer's disease (AD) clinical symptoms and therefore brain Aβ load measured using PET serves as a gold standard biomarker for the early diagnosis of AD. However, the uneconomical nature of PET makes blood markers, that reflect brain Aβ...
Article
Purpose: Economic conditions have created a tough competition between companies in the industry. The large companies, seek to obtain, acquire, develop, utilize, maintain and disclose strategic resources to the fullest. The paper aims to examine the effects of company size to company profitability and corporate value. Design/Methodology/Approach: Th...
Article
Full-text available
The kynurenine pathway (KP) is dysregulated in neuroinflammatory diseases including Alzheimer's disease (AD), however has not been investigated in preclinical AD characterized by high neocortical amyloid-β load (NAL), prior to cognitive impairment. Serum KP metabolites were measured in the cognitively normal KARVIAH cohort. Participants, aged 65-90...
Article
Full-text available
Background: The disruption of neurofilament, an axonal cytoskeletal protein, in neurodegenerative conditions may result in neuronal damage and its release into the cerebrospinal fluid and blood. In Alzheimer's disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood. Objective: Inve...
Chapter
Genetically modified mouse models have been instrumental in deciphering pathomechanisms in a large variety of human conditions. Accordingly, transgenic and knockout mice have contributed to understanding neurodegenerative processes in Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD). While initial models for AD and FTLD based o...
Article
Full-text available
Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by seve...
Article
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing and fatal disease characterized by muscular atrophy due to loss of upper and lower motor neurons. Histopathologically, the majority of ALS cases present with abnormal cytoplasmic accumulation and aggregation of the nuclear RNA-regulating protein TAR DNA-binding protein 43 (TDP-43). Pathog...
Article
Full-text available
Brain and blood fatty acids (FA) are altered in Alzheimer’s disease and cognitively impaired individuals, however, FA alterations in the preclinical phase, prior to cognitive impairment have not been investigated previously. The current study therefore evaluated erythrocyte FA in cognitively normal elderly participants aged 65–90 years via trans-me...
Conference Paper
https://combio2017.combio.org.au/abstract.php?id=172
Article
Full-text available
Ferritin, an iron storage and regulation protein, has been associated with Alzheimer's disease (AD); however, it has not been investigated in preclinical AD, detected by neocortical amyloid-β load (NAL), before cognitive impairment. Cross-sectional analyses were carried out for plasma and serum ferritin in participants in the Kerr Anglican Retireme...
Article
Evidence in support of links between type-2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) has increased considerably in recent years. AD pathological hallmarks include the accumulation of extracellular amyloid-β (Aβ) and intracellular hyperphosphorylated tau in the brain, which are hypothesized to promote inflammation, oxidative stress, and...
Data
Supplementary material is available on the publishers Web site along with the published article.
Article
Full-text available
Reduction in testosterone levels in men during aging is associated with cognitive decline and risk of dementia. Animal studies have shown benefits for testosterone supplementation in improving cognition and reducing Alzheimer's disease pathology. In a randomized, placebo-controlled, crossover study of men with subjective memory complaint and low te...
Article
Hormonal changes associated with ageing have been implicated in the pathogenesis of Alzheimer's disease (AD), the most common form of dementia. Reductions in serum testosterone and increases in luteinizing hormone (LH) are established AD risk factors for dementia in men and have important roles in modulating AD pathogenesis. One of the defining fea...
Article
Full-text available
Testosterone replacement therapy (TRT) has been investigated in older men as a preventative treatment against Alzheimer's disease and dementia. However, previous studies have been contradictory. We assessed TRT physiological effects in 44 older men (aged 61 + 7.7 years) with subjective memory complaints using a double blind, randomized, cross-over,...
Article
Full-text available
SUMMARY A beta (Aβ or β-amyloid) is a key molecule in Alzheimer's disease (AD) pathogenesis. According to the 'amyloid hypothesis', the gradual accumulation of Aβ triggers events which results in neuronal loss in regions of the brain involved with memory and learning. Diverse agents have been developed to reduce brain Aβ accumulation or to enhance...
Conference Paper
Reductions in sex steroids and neurosteroid production have been reported in AD brain. Hormonal supplementation has shown benefits in offering neuroprotection and reducing cerebral amyloid load in animal studies. Although requiring further investigation in clinical trials, concerns have been raised with long-term therapeutic application due to pote...

Questions and Answers

,

Projects

Project (1)